Analysts Set Benitec Biopharma Limited (NASDAQ:BNTC) Target Price at $24.80

Posted by George Bondi on Aug 29th, 2026

Shares of Benitec Biopharma Limited (NASDAQ:BNTC – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $24.80.

BNTC has been the topic of several analyst reports. Guggenheim cut shares of Benitec Biopharma from a “buy” rating to a “neutral” rating in a report on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Friday, July 17th. Wedbush initiated coverage on Benitec Biopharma in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $16.00 target price on the stock. Evercore assumed coverage on Benitec Biopharma in a research report on Tuesday, May 12th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Wall Street Zen raised Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st.

Get Our Latest Research Report on Benitec Biopharma

Institutional Trading of Benitec Biopharma

A number of large investors have recently added to or reduced their stakes in BNTC. AWM Investment Company Inc. purchased a new position in Benitec Biopharma in the second quarter valued at about $2,515,000. MYDA Advisors LLC grew its position in shares of Benitec Biopharma by 221.4% during the 4th quarter. MYDA Advisors LLC now owns 225,000 shares of the biotechnology company’s stock valued at $3,031,000 after acquiring an additional 155,000 shares during the period. Simplify Asset Management Inc. increased its stake in shares of Benitec Biopharma by 271.9% during the 1st quarter. Simplify Asset Management Inc. now owns 562,242 shares of the biotechnology company’s stock worth $5,988,000 after purchasing an additional 411,079 shares during the last quarter. Empery Asset Management LP purchased a new stake in shares of Benitec Biopharma during the 4th quarter worth approximately $747,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Benitec Biopharma in the 2nd quarter worth approximately $804,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Price Performance

NASDAQ BNTC opened at $12.47 on Friday. The company has a fifty day moving average price of $12.73 and a 200-day moving average price of $11.92. The firm has a market cap of $428.34 million, a price-to-earnings ratio of -10.94 and a beta of 0.28. Benitec Biopharma has a 1 year low of $9.85 and a 1 year high of $16.76.

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.